1
|
Yu Y, Gao C, Chen Y, Wang M, Zhang J, Ma X, Liu S, Yuan H, Li Z, Niu H. Copy Number Analysis Reveal Genetic Risks of Penile Cancer. Front Oncol 2021; 10:596261. [PMID: 33381457 PMCID: PMC7768990 DOI: 10.3389/fonc.2020.596261] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Accepted: 11/10/2020] [Indexed: 11/16/2022] Open
Abstract
Objectives To evaluate copy number alterations (CNAs) in genes associated with penile cancer (PeC) and determine their correlation and prognostic ability with PeC. Methods Whole-exome sequencing was performed for tumor tissue and matched normal DNA of 35 patients diagnosed with penile squamous cell carcinoma from 2011 to 2016. Somatic CNAs were detected using the Genome Analysis Toolkit (GATK). Retrospective clinical data were collected and analyzed. All the data were statistically analyzed using SPSS 16.0 software. The cancer-specific survival rates were estimated by Kaplan-Meier curves and compared with the log-rank test. Results CNAs in the MYCN gene was detected in 19 (amplification: 54.29%) patients. Other CNAs gene targets were FAK (amplification: 45.72%, deletion: 8.57%), TP53 (amplification: 2.86%, deletion: 51.43%), TRKA (amplification: 34.29%, deletion: 2.86%), p75NTR (amplification: 5.71%, deletion: 42.86%), Miz-1 (amplification: 14.29%, deletion: 20.00%), Max (amplification: 17.14%, deletion: 2.86%), Bmi1 (amplification:14.29%, deletion: 48.57%), and MDM2 (amplification: 5.71%, deletion: 45.72%). The CNAs in MYCN and FAK correlated significantly with patient prognosis (P<0.05). The 3-year Recurrence-free survival rate was 87.10% among patients followed up. The 5-year survival rate of patients with MYCN amplification was 69.2%, compared to 94.4% in the non-amplification group. The 5-year survival rate of patients with FAK amplification was 65.6%, compared to 94.7% in the non-amplification group. The PPI network showed that TP53 and MYCN might play meaningful functional roles in PeC. Conclusion MYCN and FAK amplification and TP53 deletion were apparent in PeC. MYCN and TP53 were hub genes in PeC. MYCN and FAK amplification was also detected and analyzed, and the findings indicated that these two genes are predictors of poor prognosis in PeC.
Collapse
Affiliation(s)
- Yongbo Yu
- Urology Department, The Affiliated Hospital of Qingdao University, Qingdao, China
| | - Chengwen Gao
- Urology Department, The Affiliated Hospital of Qingdao University, Qingdao, China.,Laboratory of Medical Biology, Medical Research Center, The Affiliated Hospital of Qingdao University & The Biomedical Sciences Institute of Qingdao University (Qingdao Branch of SJTU Bio-X Institutes), Qingdao University, Qingdao, China
| | - Yuanbin Chen
- Urology Department, The Affiliated Hospital of Qingdao University, Qingdao, China
| | - Meilan Wang
- Nursing Department, The Shengli College, China University of Petroleum, Dongying, China
| | - Jianfeng Zhang
- Urology Department, The Affiliated Hospital of Qingdao University, Qingdao, China
| | - Xiaocheng Ma
- Urology Department, The Affiliated Hospital of Qingdao University, Qingdao, China
| | - Shuaihong Liu
- Urology Department, The Affiliated Hospital of Qingdao University, Qingdao, China
| | - Hang Yuan
- Urology Department, The Affiliated Hospital of Qingdao University, Qingdao, China
| | - Zhiqiang Li
- Urology Department, The Affiliated Hospital of Qingdao University, Qingdao, China.,Laboratory of Medical Biology, Medical Research Center, The Affiliated Hospital of Qingdao University & The Biomedical Sciences Institute of Qingdao University (Qingdao Branch of SJTU Bio-X Institutes), Qingdao University, Qingdao, China
| | - Haitao Niu
- Urology Department, The Affiliated Hospital of Qingdao University, Qingdao, China
| |
Collapse
|
2
|
Risk factors and molecular characterization of penile cancer: impact on prognosis and potential targets for systemic therapy. Curr Opin Urol 2020; 30:202-207. [PMID: 31895076 DOI: 10.1097/mou.0000000000000712] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
PURPOSE OF REVIEW To provide a comprehensive summary of risk factors, molecular machinery as well as potential therapeutic targets with a particular focus on literature published in the last 2 years on prognosis and treatment of penile cancer (PeCa). RECENT FINDINGS E2F, LAMC2, MAML2, ID1 and IGFBP2 proteins were demonstrated to play a critical role for aggressive tumor behavior and might predict poor survival in PeCa. PD-L1 axis was confirmed as a promising pathway to serve as a therapeutic target. A number of genetic alterations were illuminated. In clinical testing, pan-HER tyrosine kinase inhibitor dacomitinib provided promising results in chemo-naïve and EGFR monoantibody nimotuzumab in chemotherapy-failed PeCa patients. SUMMARY Knowledge of prognosis-relevant altered molecular pathways in PeCa is expanding paving the way for identification of potential therapeutic targets. Multicenter clinical trials in the setting of centralized PeCa care are warranted to foster effective marker-based individualized treatment strategies.
Collapse
|
3
|
Macedo J, Silva E, Nogueira L, Coelho R, da Silva J, Dos Santos A, Teixeira-Júnior AA, Belfort M, Silva G, Khayat A, de Oliveira E, Dos Santos AP, Cavalli LR, Pereira SR. Genomic profiling reveals the pivotal role of hrHPV driving copy number and gene expression alterations, including mRNA downregulation of TP53 and RB1 in penile cancer. Mol Carcinog 2020; 59:604-617. [PMID: 32212199 DOI: 10.1002/mc.23185] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2019] [Revised: 02/26/2020] [Accepted: 03/02/2020] [Indexed: 12/13/2022]
Abstract
The incidence of penile cancer (PeCa) is increasing worldwide, however, the highest rates are reported in underdeveloped countries. The molecular mechanisms that underly the onset and progression of these tumors are still unclear. Therefore, our goal was to determine the genome-wide copy number alterations and the involvement of human papiloma virus (HPV) (TP53 and RB1), inflammatory (COX2 and EGFR), and PI3K/AKT pathway (AKT1, AKT2, EGFR, ERBB3, ERBB4, PIK3CA, and PTEN) associated genes in patients with PeCa from a high incidence region in Brazil (Maranhão). HPV genotyping was performed by nest-PCR and genome sequencing, copy number alterations (CNAs) by array comparative genomic hybridization and gene copy number status, gene, and protein expression by quantitative polymerase chain reaction, reverse transcriptase-quantitative polymerase chain reaction, and immunohistochemistry, respectively. HPV genotyping revealed one of the highest frequencies of HPV reported in PeCa, affecting 96.4% of the cases. The most common CNAs observed were located at the HPV integration sites, such as 2p12-p11.2 and 14q32.33, where ADAM 6, KIAA0125, LINC00226, LINC00221, and miR7641-2, are mapped. Increased copy number of ERBB3 and EGFR genes were observed in association with COX2 and EGFR overexpression, reinforcing the role of the inflammatory pathway in PeCa, and suggesting anti-EGFR and anti-COX2 inhibitors as promising therapies for PeCa. Additionally, TP53 and RB1 messenger RNA downregulation was observed, suggesting the occurrence of other mechanisms for repression of these oncoproteins, in addition to the canonical HPV/TP53/RB1 signaling pathway. Our data reinforce the role of epigenetic events in abnormal gene expression in HPV-associated carcinomas and suggest the pivotal role of HPV driving CNAs and controlling gene expression in PeCa.
Collapse
Affiliation(s)
- Juliana Macedo
- Postgraduate Program in Health Science, Federal University of Maranhão, São Luís, Maranhão, Brazil
| | - Elis Silva
- Laboratory of Genetics and Molecular Biology, Department of Biology, Federal University of Maranhão, São Luís, Maranhão, Brazil
| | | | - Ronald Coelho
- Aldenora Bello Cancer Hospital, São Luís, Maranhão, Brazil
| | - Jenilson da Silva
- Postgraduate Program in Health Science, Federal University of Maranhão, São Luís, Maranhão, Brazil.,Laboratory of Genetics and Molecular Biology, Department of Biology, Federal University of Maranhão, São Luís, Maranhão, Brazil
| | - Alcione Dos Santos
- Public Health Department, Federal University of Maranhão, São Luís, Maranhão, Brazil
| | | | - Marta Belfort
- Postgraduate Program in Health Science, Federal University of Maranhão, São Luís, Maranhão, Brazil
| | - Gyl Silva
- Biology Undergraduate Course, Department of Pathology, Federal University of Maranhão, São Luís, Maranhão, Brazil
| | - André Khayat
- Oncology Research Center, Federal University of Pará, Belém, Pará, Brazil
| | - Edivaldo de Oliveira
- Tissue Culture and Cytogenetics Laboratory, Institute of Evandro Chagas, Belém, Pará, Brazil
| | - Ana Paula Dos Santos
- Department of Physiological Sciences, Federal University of Maranhão, São Luís, Maranhão, Brazil
| | - Luciane R Cavalli
- Faculdades Pequeno Príncipe, Instituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, Paraná, Brazil.,Department of Oncology, Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
| | - Silma Regina Pereira
- Laboratory of Genetics and Molecular Biology, Department of Biology, Federal University of Maranhão, São Luís, Maranhão, Brazil
| |
Collapse
|
4
|
Hervás-Marín D, Higgins F, Sanmartín O, López-Guerrero JA, Bañó MC, Igual JC, Quilis I, Sandoval J. Genome wide DNA methylation profiling identifies specific epigenetic features in high-risk cutaneous squamous cell carcinoma. PLoS One 2019; 14:e0223341. [PMID: 31860637 PMCID: PMC6924689 DOI: 10.1371/journal.pone.0223341] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2019] [Accepted: 12/06/2019] [Indexed: 01/23/2023] Open
Abstract
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer. Although most cSCCs have good prognosis, a subgroup of high-risk cSCC has a higher frequency of recurrence and mortality. Therefore, the identification of molecular risk factors associated with this aggressive subtype is of major interest. In this work we carried out a global-scale approach to investigate the DNA-methylation profile in patients at different stages, from premalignant actinic keratosis to low-risk invasive and high-risk non-metastatic and metastatic cSCC. The results showed massive non-sequential changes in DNA-methylome and identified a minimal methylation signature that discriminates between stages. Importantly, a direct comparison of low-risk and high-risk stages revealed epigenetic traits characteristic of high-risk tumours. Finally, a prognostic prediction model in cSCC patients identified a methylation signature able to predict the overall survival of patients. Thus, the analysis of DNA-methylation in cSCC revealed changes during the evolution of the disease through the different stages that can be of great value not only in the diagnosis but also in the prognosis of the disease.
Collapse
Affiliation(s)
- David Hervás-Marín
- Department of Biostatistics, Instituto de Investigación Sanitaria La Fe, Valencia, Spain
| | - Faatiemah Higgins
- Estructura de Recerca Interdisciplinar en Biotecnologia i Biomedicina (ERI BIOTECMED) Universitat de València, Burjassot, Valencia, Spain
- Departament de Bioquímica i Biologia Molecular, Universitat de València, Burjassot, Valencia, Spain
| | - Onofre Sanmartín
- Dermatology Department, Instituto Valenciano de Oncología, Valencia, Spain
- Facultad de Medicina, Universidad Católica de Valencia, Valencia, Spain
| | | | - M. Carmen Bañó
- Estructura de Recerca Interdisciplinar en Biotecnologia i Biomedicina (ERI BIOTECMED) Universitat de València, Burjassot, Valencia, Spain
- Departament de Bioquímica i Biologia Molecular, Universitat de València, Burjassot, Valencia, Spain
| | - J. Carlos Igual
- Estructura de Recerca Interdisciplinar en Biotecnologia i Biomedicina (ERI BIOTECMED) Universitat de València, Burjassot, Valencia, Spain
- Departament de Bioquímica i Biologia Molecular, Universitat de València, Burjassot, Valencia, Spain
| | - Inma Quilis
- Estructura de Recerca Interdisciplinar en Biotecnologia i Biomedicina (ERI BIOTECMED) Universitat de València, Burjassot, Valencia, Spain
- Departament de Bioquímica i Biologia Molecular, Universitat de València, Burjassot, Valencia, Spain
| | - Juan Sandoval
- Biomarkers and Precision Medicine Unit (UByMP), Instituto de Investigación Sanitaria La Fe, Valencia, Spain
| |
Collapse
|
5
|
Kamel MH, Khalil MI, Davis R, Spiess PE. Management of the Clinically Negative (cN0) Groin Penile Cancer Patient: A Review. Urology 2019; 131:5-13. [PMID: 31129195 DOI: 10.1016/j.urology.2019.05.005] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2019] [Revised: 05/08/2019] [Accepted: 05/10/2019] [Indexed: 01/05/2023]
Abstract
To determine the role of noninvasive, minimally invasive diagnostic modalities and current management recommendations for cN0 PNC, a literature review using PubMed and Web of Science search engines were conducted. We found that for predicting ILN+: physical exam has limitations, nomograms are not validated, conventional computerized tomography/magnetic resonance imaging/positron imaging tomography scans have minimal role, and dynamic sentinel lymph node biopsy is the most reliable minimally invasive modality. Adverse pathological features: G3, stage ≥ T2, presence of LVI, and rare histopathological variants are important predictors of ILN+ and their presence warrants prophylactic ILND or dynamic sentinel lymph node biopsy. In the absence of these adverse pathological features conservative management is justified.
Collapse
Affiliation(s)
- Mohamed H Kamel
- Department of Urology, University of Arkansas for Medical Sciences, Little Rock, AR
| | - Mahmoud I Khalil
- Department of Urology, University of Arkansas for Medical Sciences, Little Rock, AR
| | - Rodney Davis
- Department of Urology, University of Arkansas for Medical Sciences, Little Rock, AR
| | - Philippe E Spiess
- Department of Genito-urinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
| |
Collapse
|
6
|
Hakenberg OW, Dräger D, Erbersdobler A. Pathology, Molecular Biology, and Prognosis of Penile Squamous Cell Carcinoma: What Can We Learn from the Specimen? EUROPEAN UROLOGY SUPPLEMENTS 2018; 17:138-145. [DOI: 10.1016/j.eursup.2018.05.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 08/30/2023]
|
7
|
May M, Brookman-May SD, Ecke TH, Burger M. Die molekulare Charakterisierung des Peniskarzinoms. Urologe A 2018; 57:398-407. [DOI: 10.1007/s00120-018-0596-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
8
|
Peta E, Cappellesso R, Masi G, Sinigaglia A, Trevisan M, Grassi A, Di Camillo B, Vassarotto E, Fassina A, Palù G, Barzon L. Down-regulation of microRNA-146a is associated with high-risk human papillomavirus infection and epidermal growth factor receptor overexpression in penile squamous cell carcinoma. Hum Pathol 2017; 61:33-40. [DOI: 10.1016/j.humpath.2016.10.019] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/19/2016] [Revised: 10/03/2016] [Accepted: 10/13/2016] [Indexed: 12/30/2022]
|
9
|
Spiess PE, Dhillon J, Baumgarten AS, Johnstone PA, Giuliano AR. Pathophysiological basis of human papillomavirus in penile cancer: Key to prevention and delivery of more effective therapies. CA Cancer J Clin 2016; 66:481-495. [PMID: 27314890 DOI: 10.3322/caac.21354] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Answer questions and earn CME/CNE Squamous cell carcinoma (SCC) of the penis is a rare malignancy in the United States, with a significantly higher incidence-up to 20 to 30 times greater-in areas of Africa and South America. This can be explained in part by the significantly greater prevalence of sexually transmitted diseases among high-risk males often having unprotected sex with multiple sexual partners. Human papillomavirus (HPV) has been implicated as the infectious pathway by which several these penile neoplasms originate from precursor lesions. In this regard, a fundamental understanding of HPV in penile carcinogenesis can have meaningful implications in understanding 1) the diagnosis of HPV-related precursor penile lesions, 2) targeting HPV-specific molecular pathways, and 3) cancer prevention. Using vaccination programs not only may improve patient outcomes but also may minimize the need for highly aggressive and often debilitating surgical resection. CA Cancer J Clin 2016;66:481-495. © 2016 American Cancer Society.
Collapse
Affiliation(s)
- Philippe E Spiess
- Associate Member, Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL
| | - Jasreman Dhillon
- Assistant Member, Department of Anatomical Pathology, Moffitt Cancer Center, Tampa, FL
| | - Adam S Baumgarten
- Urology Resident Physician, Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL
| | - Peter A Johnstone
- Senior Member, Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL
| | - Anna R Giuliano
- Senior Member, Department of Infection and Cancer, Moffitt Cancer Center, Tampa, FL
| |
Collapse
|
10
|
Arya M, Thrasivoulou C, Henrique R, Millar M, Hamblin R, Davda R, Aare K, Masters JR, Thomson C, Muneer A, Patel HRH, Ahmed A. Targets of Wnt/ß-catenin transcription in penile carcinoma. PLoS One 2015; 10:e0124395. [PMID: 25901368 PMCID: PMC4406530 DOI: 10.1371/journal.pone.0124395] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2014] [Accepted: 03/13/2015] [Indexed: 12/21/2022] Open
Abstract
Penile squamous cell carcinoma (PeCa) is a rare malignancy and little is known regarding the molecular mechanisms involved in carcinogenesis of PeCa. The Wnt signaling pathway, with the transcription activator ß-catenin as a major transducer, is a key cellular pathway during development and in disease, particularly cancer. We have used PeCa tissue arrays and multi-fluorophore labelled, quantitative, immunohistochemistry to interrogate the expression of WNT4, a Wnt ligand, and three targets of Wnt-ß-catenin transcription activation, namely, MMP7, cyclinD1 (CD1) and c-MYC in 141 penile tissue cores from 101 unique samples. The expression of all Wnt signaling proteins tested was increased by 1.6 to 3 fold in PeCa samples compared to control tissue (normal or cancer adjacent) samples (p<0.01). Expression of all proteins, except CD1, showed a significant decrease in grade II compared to grade I tumors. High magnification, deconvolved confocal images were used to measure differences in co-localization between the four proteins. Significant (p<0.04-0.0001) differences were observed for various permutations of the combinations of proteins and state of the tissue (control, tumor grades I and II). Wnt signaling may play an important role in PeCa and proteins of the Wnt signaling network could be useful targets for diagnosis and prognostic stratification of disease.
Collapse
Affiliation(s)
- Manit Arya
- Division of Surgery, University College Hospital, London, United Kingdom and The Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
| | - Christopher Thrasivoulou
- Research Department of Cell and Developmental Biology, The Centre for Cell and Molecular Dynamics, Rockefeller Building, University College London, London, United Kingdom
| | - Rui Henrique
- Department of Pathology, Portuguese Oncology Institute and Department of Pathology and Molecular Immunology, Abel Salazar Institute of Biomedical Sciences, University of Porto, Porto, Portugal
| | - Michael Millar
- Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom
| | - Ruth Hamblin
- Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom
| | - Reena Davda
- Prostate Cancer Research Centre, Division of Surgery, University College London, London, United Kingdom
| | - Kristina Aare
- Prostate Cancer Research Centre, Division of Surgery, University College London, London, United Kingdom
| | - John R. Masters
- Prostate Cancer Research Centre, Division of Surgery, University College London, London, United Kingdom
| | - Calum Thomson
- Dundee Imaging Facility, College of Life Sciences, University of Dundee, Dundee, United Kingdom
| | - Asif Muneer
- Department of Urology, University College Hospital, London, United Kingdom
| | - Hitendra R. H. Patel
- Division of Surgery, Oncology, Urology and Women's Health, University Hospital of Northern Norway, Tromso, Norway
| | - Aamir Ahmed
- Prostate Cancer Research Centre, Division of Surgery, University College London, London, United Kingdom
- * E-mail:
| |
Collapse
|
11
|
Masferrer E, Ferrándiz-Pulido C, Masferrer-Niubò M, Rodríguez-Rodríguez A, Gil I, Pont A, Servitje O, García de Herreros A, Lloveras B, García-Patos V, Pujol RM, Toll A, Hernández-Muñoz I. Epithelial-to-Mesenchymal Transition in Penile Squamous Cell Carcinoma. J Urol 2015; 193:699-705. [DOI: 10.1016/j.juro.2014.07.083] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/14/2014] [Indexed: 10/25/2022]
Affiliation(s)
- Emili Masferrer
- Department of Dermatology, Facultat de Medicina, Universitat de Barcelona, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques, Universitat Pompeu Fabra (EM), Barcelona, Spain
- Department of Pathology (BL), Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
- Department of Dermatology (RMP, AT), Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
- Department of Dermatology, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona (CF-P, VG-P), Barcelona, Spain
- Department of Urology, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques (AR-R), Barcelona, Spain
| | - Carla Ferrándiz-Pulido
- Department of Dermatology, Facultat de Medicina, Universitat de Barcelona, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques, Universitat Pompeu Fabra (EM), Barcelona, Spain
- Department of Pathology (BL), Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
- Department of Dermatology (RMP, AT), Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
- Department of Dermatology, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona (CF-P, VG-P), Barcelona, Spain
- Department of Urology, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques (AR-R), Barcelona, Spain
| | - Magalí Masferrer-Niubò
- Department of Dermatology, Facultat de Medicina, Universitat de Barcelona, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques, Universitat Pompeu Fabra (EM), Barcelona, Spain
- Department of Pathology (BL), Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
- Department of Dermatology (RMP, AT), Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
- Department of Dermatology, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona (CF-P, VG-P), Barcelona, Spain
- Department of Urology, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques (AR-R), Barcelona, Spain
| | - Alfredo Rodríguez-Rodríguez
- Department of Dermatology, Facultat de Medicina, Universitat de Barcelona, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques, Universitat Pompeu Fabra (EM), Barcelona, Spain
- Department of Pathology (BL), Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
- Department of Dermatology (RMP, AT), Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
- Department of Dermatology, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona (CF-P, VG-P), Barcelona, Spain
- Department of Urology, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques (AR-R), Barcelona, Spain
| | - Inmaculada Gil
- Department of Dermatology, Facultat de Medicina, Universitat de Barcelona, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques, Universitat Pompeu Fabra (EM), Barcelona, Spain
- Department of Pathology (BL), Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
- Department of Dermatology (RMP, AT), Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
- Department of Dermatology, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona (CF-P, VG-P), Barcelona, Spain
- Department of Urology, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques (AR-R), Barcelona, Spain
| | - Antoni Pont
- Department of Dermatology, Facultat de Medicina, Universitat de Barcelona, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques, Universitat Pompeu Fabra (EM), Barcelona, Spain
- Department of Pathology (BL), Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
- Department of Dermatology (RMP, AT), Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
- Department of Dermatology, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona (CF-P, VG-P), Barcelona, Spain
- Department of Urology, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques (AR-R), Barcelona, Spain
| | - Octavi Servitje
- Department of Dermatology, Facultat de Medicina, Universitat de Barcelona, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques, Universitat Pompeu Fabra (EM), Barcelona, Spain
- Department of Pathology (BL), Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
- Department of Dermatology (RMP, AT), Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
- Department of Dermatology, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona (CF-P, VG-P), Barcelona, Spain
- Department of Urology, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques (AR-R), Barcelona, Spain
| | - Antonio García de Herreros
- Department of Dermatology, Facultat de Medicina, Universitat de Barcelona, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques, Universitat Pompeu Fabra (EM), Barcelona, Spain
- Department of Pathology (BL), Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
- Department of Dermatology (RMP, AT), Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
- Department of Dermatology, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona (CF-P, VG-P), Barcelona, Spain
- Department of Urology, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques (AR-R), Barcelona, Spain
| | - Belen Lloveras
- Department of Dermatology, Facultat de Medicina, Universitat de Barcelona, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques, Universitat Pompeu Fabra (EM), Barcelona, Spain
- Department of Pathology (BL), Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
- Department of Dermatology (RMP, AT), Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
- Department of Dermatology, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona (CF-P, VG-P), Barcelona, Spain
- Department of Urology, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques (AR-R), Barcelona, Spain
| | - Vicenç García-Patos
- Department of Dermatology, Facultat de Medicina, Universitat de Barcelona, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques, Universitat Pompeu Fabra (EM), Barcelona, Spain
- Department of Pathology (BL), Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
- Department of Dermatology (RMP, AT), Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
- Department of Dermatology, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona (CF-P, VG-P), Barcelona, Spain
- Department of Urology, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques (AR-R), Barcelona, Spain
| | - Ramon M. Pujol
- Department of Dermatology, Facultat de Medicina, Universitat de Barcelona, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques, Universitat Pompeu Fabra (EM), Barcelona, Spain
- Department of Pathology (BL), Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
- Department of Dermatology (RMP, AT), Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
- Department of Dermatology, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona (CF-P, VG-P), Barcelona, Spain
- Department of Urology, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques (AR-R), Barcelona, Spain
| | - Agustí Toll
- Department of Dermatology, Facultat de Medicina, Universitat de Barcelona, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques, Universitat Pompeu Fabra (EM), Barcelona, Spain
- Department of Pathology (BL), Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
- Department of Dermatology (RMP, AT), Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
- Department of Dermatology, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona (CF-P, VG-P), Barcelona, Spain
- Department of Urology, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques (AR-R), Barcelona, Spain
| | - Inmaculada Hernández-Muñoz
- Department of Dermatology, Facultat de Medicina, Universitat de Barcelona, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques, Universitat Pompeu Fabra (EM), Barcelona, Spain
- Department of Pathology (BL), Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
- Department of Dermatology (RMP, AT), Hospital del Mar, Parc de Salut Mar, Barcelona, Spain
- Department of Dermatology, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona (CF-P, VG-P), Barcelona, Spain
- Department of Urology, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques (AR-R), Barcelona, Spain
| |
Collapse
|
12
|
Busso-Lopes AF, Marchi FA, Kuasne H, Scapulatempo-Neto C, Trindade-Filho JCS, de Jesus CMN, Lopes A, Guimarães GC, Rogatto SR. Genomic profiling of human penile carcinoma predicts worse prognosis and survival. Cancer Prev Res (Phila) 2014; 8:149-56. [PMID: 25502573 DOI: 10.1158/1940-6207.capr-14-0284] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The molecular mechanisms underlying penile carcinoma are still poorly understood, and the detection of genetic markers would be of great benefit for these patients. In this study, we assessed the genomic profile aiming at identifying potential prognostic biomarkers in penile carcinoma. Globally, 46 penile carcinoma samples were considered to evaluate DNA copy-number alterations via array comparative genomic hybridization (aCGH) combined with human papillomavirus (HPV) genotyping. Specific genes were investigated by using qPCR, FISH, and RT-qPCR. Genomic alterations mapped at 3p and 8p were related to worse prognostic features, including advanced T and clinical stage, recurrence and death from the disease. Losses of 3p21.1-p14.3 and gains of 3q25.31-q29 were associated with reduced cancer-specific and disease-free survival. Genomic alterations detected for chromosome 3 (LAMP3, PPARG, TNFSF10 genes) and 8 (DLC1) were evaluated by qPCR. DLC1 and PPARG losses were associated with poor prognosis characteristics. Losses of DLC1 were an independent risk factor for recurrence on multivariate analysis. The gene-expression analysis showed downexpression of DLC1 and PPARG and overexpression of LAMP3 and TNFSF10 genes. Chromosome Y losses and MYC gene (8q24) gains were confirmed by FISH. HPV infection was detected in 34.8% of the samples, and 19 differential genomic regions were obtained related to viral status. At first time, we described recurrent copy-number alterations and its potential prognostic value in penile carcinomas. We also showed a specific genomic profile according to HPV infection, supporting the hypothesis that penile tumors present distinct etiologies according to virus status.
Collapse
Affiliation(s)
- Ariane F Busso-Lopes
- CIPE-Cancer Treatment and Research Center, AC Camargo Cancer Center, São Paulo, Brazil
| | - Fábio A Marchi
- CIPE-Cancer Treatment and Research Center, AC Camargo Cancer Center, São Paulo, Brazil
| | - Hellen Kuasne
- CIPE-Cancer Treatment and Research Center, AC Camargo Cancer Center, São Paulo, Brazil. Department of Urology, Faculty of Medicine, UNESP, Botucatu, São Paulo, Brazil
| | | | | | | | - Ademar Lopes
- Department of Pelvic Surgery, AC Camargo Cancer Center, São Paulo, Brazil
| | | | - Silvia R Rogatto
- CIPE-Cancer Treatment and Research Center, AC Camargo Cancer Center, São Paulo, Brazil. Department of Urology, Faculty of Medicine, UNESP, Botucatu, São Paulo, Brazil.
| |
Collapse
|
13
|
Houldsworth J. FHACT: the FISH-based HPV-associated cancer test that detects nonrandom gain at four genomic loci as biomarkers of disease progression. Expert Rev Mol Diagn 2014; 14:921-34. [DOI: 10.1586/14737159.2014.965685] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
|
14
|
Protzel C, Spiess PE. Molecular research in penile cancer-lessons learned from the past and bright horizons of the future? Int J Mol Sci 2013; 14:19494-505. [PMID: 24077122 PMCID: PMC3821569 DOI: 10.3390/ijms141019494] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2013] [Revised: 09/11/2013] [Accepted: 09/12/2013] [Indexed: 02/06/2023] Open
Abstract
Penile cancer is a rare tumor. There is a limited understanding of the biological mediators of prognostic and therapeutic importance in penile cancer. However, there exists some fundamental understanding of the major pathways involved in the development of penile pre-neoplastic lesions and neoplasms. The aim of the present review is to highlight our current state of molecular knowledge in penile cancer to foster the necessary tools for researchers to pave major advancements in our current treatment paradigms and cancer specific outcomes.
Collapse
Affiliation(s)
- Chris Protzel
- Department of Urology, University of Rostock, Rostock 18055, Germany; E-Mail:
| | - Philippe E. Spiess
- Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
- Author to whom correspondence should be addressed; E-Mail: ; Tel.: +1-813-745-2484; Fax: +1-813-745-8494
| |
Collapse
|
15
|
Li D, Han Z, Liu J, Zhang X, Ren J, Yan L, Liu H, Xu Z. Upregulation of nucleus HDGF predicts poor prognostic outcome in patients with penile squamous cell carcinoma bypass VEGF-A and Ki-67. Med Oncol 2013; 30:702. [PMID: 23999841 DOI: 10.1007/s12032-013-0702-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2013] [Accepted: 08/20/2013] [Indexed: 01/27/2023]
Abstract
Hepatoma-derived growth factor (HDGF) has been verified to serve as a credible prognostic marker for several types of cancers, but its role in urologic carcinomas remains undetermined. In this study, we analyzed the significance of HDGF, as well as its relative factors such as vascular endothelial growth factor-A (VEGF-A) and Ki-67, in penile squamous cell carcinoma (PSCC). Formalin-fixed paraffin-embedded PSCC samples from 54 patients receiving surgery at Qilu Hospital of Shandong University were included in the retrospective study. The expressions of HDGF, VEGF-A, and Ki-67 were detected by immunohistochemistry of a non-biotin polymerized horseradish peroxidase method. The relationships between the expressions of HDGF and VEGF-A, Ki-67 were assessed. Moreover, their correlations with clinical pathologic characteristics and disease prognosis were, respectively, evaluated. HDGF, VEGF-A, and Ki-67 were positively expressed in 28 (51.9%), 29 (53.7%), and 26 (48.1%) patients, respectively. The expressions of VEGF-A and Ki-67 were closely correlated with PSCC type (P < 0.05). A statistically significant relationship between the expressions of HDGF and VEGF-A in PSCC was observed (P = 0.03). Patients with symptom interval of more than 6 months had a significantly poorer survival rate than those with symptom interval less than 6 months (43.3 vs. 70.8%, P = 0.043). Patients with positive HDGF expression also showed a significantly poorer survival rate than those with negative HDGF expression (39.3 vs. 73.1%, P = 0.013). Logistic regression demonstrated that the expression level of HDGF was an independent predictor for the prognosis of postoperative patients. The expression of HDGF significantly correlated with VEGF-A, but not Ki-67 expression. Overexpression of HDGF, rather than VEGF-A or Ki-67, was confirmed to be an independent prognosticator of poor outcome for PSCC patients.
Collapse
Affiliation(s)
- Dawei Li
- Department of Urology, Qilu Hospital of Shandong University, Jinan, 250012, People's Republic of China,
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Ferrandiz-Pulido C, Masferrer E, Toll A, Hernandez-Losa J, Mojal S, Pujol RM, Ramon y Cajal S, de Torres I, Garcia-Patos V. mTOR signaling pathway in penile squamous cell carcinoma: pmTOR and peIF4E over expression correlate with aggressive tumor behavior. J Urol 2013; 190:2288-95. [PMID: 23764082 DOI: 10.1016/j.juro.2013.06.015] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/03/2013] [Indexed: 01/01/2023]
Abstract
PURPOSE Penile squamous cell carcinoma is a rare neoplasm associated with a high risk of metastasis and morbidity. There are limited data on the role of the mTOR signaling pathway in penile squamous cell carcinoma carcinogenesis and tumor maintenance. We assessed a possible role for mTOR signaling pathway activation as a potential predictive biomarker of outcome and a therapeutic target for penile cancer. MATERIAL AND METHODS A cohort of 67 patients diagnosed with invasive penile squamous cell carcinoma from 1987 to 2010 who had known HPV status were selected for study. Tissue microarrays were constructed with 67 primary penile squamous cell carcinomas, matched normal tissues and 8 lymph node metastases. Immunohistochemical staining was performed for p53, pmTOR, pERK, p4E-BP1, eIF4E and peIF4E. Expression was evaluated using a semiquantitative H-score on a scale of 0 to 300. RESULTS Expression of pmTOR, p4E-BP1, eIF4E and peIF4E was increased in penile tumors compared with matched adjacent normal tissues, indicating activation of the mTOR signaling pathway in penile tumorigenesis. Over expression of pmTOR, peIF4E and p53 was significantly associated with lymph node disease. peIF4E and p53 also correlated with a poor outcome, including recurrence, metastasis or disease specific death. In contrast, pERK and p4E-BP1 were associated with lower pT stages. pmTOR and intense p53 expression was associated with HPV negative tumors. CONCLUSIONS Activation of mTOR signaling may contribute to penile squamous cell carcinoma progression and aggressive behavior. Targeting mTOR or its downstream signaling targets, such as peIF4E, may be a valid therapeutic strategy.
Collapse
Affiliation(s)
- Carla Ferrandiz-Pulido
- Department of Dermatology, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Facultat de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
|